J Korean Continence Soc.  2008 Jun;12(1):36-41.

Efficacy of terazosin for overactive bladder symptoms and sexual function in patients with overactive bladder and symptomatic benign prostatic hyperplasia: a prospective multicenter trial

  • 1Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Korea. mschoo@amc.seoul.kr
  • 2Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
  • 3Department of Urology, College of Medicine, Pusan National University, Busan, Korea.
  • 4Department of Urology, Chonnam National University Medical School, Gwangju, Korea.
  • 5Department of Urology, Seoul National University College of Medicine, Korea.
  • 6Department of Urology, The Catholic University of Korea, Seoul, Korea.


This study is to evaluate the efficacy of terazosin in the treatment of overactive bladder (OAB) symptoms and sexual dysfunction in patients with symptomatic benign prostatic hyperplasia (BPH) and OAB.
Of 200 men aged 50-80 years with symptomatic BPH, an International Prostatic Symptom Score (IPSS) > or =8 accompanied by OAB symptoms, 185 patients completed treatment with terazosin 2-5 mg once daily for 8 weeks. Patients were asked to complete a voiding diary, the International Index of Erectile Function (IIEF) questionnaire, and the IPSS at baseline, 4 and 8 weeks.
8-week terazosin treatment improved OAB symptoms as well as reducing IPSS (19.8 to 12.7) and IIEF (34.4 to 37.4) scores. OAB symptoms improved significantly, irrespective of symptom severity by the IPSS, but the IIEF score only increased in patients with severe symptoms.
Additional studies are needed to further evaluate the placebo effect. However, terazosin monotherapy is effective in patients with symptomatic BPH and OAB, and may increase sexual function in patients with severely symptomatic BPH.


Prostatic hyperplasia; Adrenergic alpha-antagonists; Erectile function; Overactive bladder

MeSH Terms

Adrenergic alpha-Antagonists
Placebo Effect
Prospective Studies*
Prostatic Hyperplasia*
Surveys and Questionnaires
Urinary Bladder, Overactive*
Adrenergic alpha-Antagonists
Full Text Links
  • JKCS
export Copy
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr